FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an isolated anti-Fc receptor-like protein 5 (FcRL5) antibody or its antigen-binding fragment, as well as to a composition, an immunoconjugate, a bispecific molecule and a kit containing it. Also disclosed is a nucleic acid molecule encoding said antibody or fragment thereof, as well as a vector and a host cell containing it. The invention also relates to a method for detecting FcRL5 in a whole cell or tissue, comprising contacting the cell or tissue with the above anti-FcRL5 antibody or antigen-binding fragment thereof.
EFFECT: invention is effective for treating a tumor expressing FcRL5.
66 cl, 16dwg, 232 tbl ,5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
